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Abstract
PURPOSE—Giant axonal neuropathy (GAN) is an inherited severe sensorimotor neuropathy. 
The aim of this research was to investigate the neuropathologic features and clinical autonomic 
nervous system (ANS) phenotype in two GAN knockout (KO) mouse models. Little is known 
about ANS involvement in GAN in humans, but autonomic signs and symptoms are commonly 
reported in early childhood.
METHODS—Routine histology and immunohistochemistry was performed on GAN KO mouse 
specimens taken at various ages. Enteric dysfunction was assessed by quantifying the frequency, 
weight, and water content of defecation in GAN KO mice.
RESULTS—Histological examination of the enteric, parasympathetic and sympathetic ANS of 
GAN KO mice revealed pronounced and widespread neuronal perikaryal intermediate filament 
inclusions. These neuronal inclusions served as an easily identifiable, early marker of GAN in 
young GAN KO mice. Functional studies identified an age-dependent alteration in fecal weight 
and defecation frequency in GAN KO mice.
CONCLUSIONS—For the first time in the GAN KO mouse model, we described the early, 
pronounced and widespread neuropathologic features involving the ANS. In addition, we provided 
evidence for a clinical autonomic phenotype in GAN KO mice, reflected in abnormal 
gastrointestinal function. These findings in GAN KO mice suggest that consideration should be 
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given to ANS involvement in human GAN, especially when considering treatments and patient 
care.
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Giant axonal neuropathy; Intermediate filaments; Gigaxonin; Autonomic nervous system; 
Neurodegenerative disease
INTRODUCTION
Giant axonal neuropathy (GAN, OMIM# 256850) is a rare, hereditary, severe motor and 
sensory axonal neuropathy with central nervous system (CNS) involvement [1]. Onset of 
symptoms is typically at 3–4 years of age and commonly heralded by clumsiness of gait. 
During the second decade of life, patients typically become wheelchair-dependent and 
progressively lose coordination and strength in their upper extremities. Death nearly always 
occurs by the second or third decade. The pathologic signature of GAN is giant axonal 
swellings, which are focally distributed and filled with densely packed accumulations of 
structurally normal neurofilaments (NFs).
From a clinical standpoint, GAN is characterized by a distally predominant peripheral 
neuropathy manifested by hypotonia, muscle atrophy, tendon contractures, and areflexia [1]. 
CNS features include prominent cerebellar dysfunction, reflected in nystagmus, dysarthria, 
dysmetria and ataxia. Detailed neuropathologic analyses of GAN have been rendered only in 
a limited number of postmortem studies.
GAN is caused by autosomal recessive loss-of-function mutations in the GAN gene that 
encodes the protein gigaxonin [1]. Gigaxonin plays a pivotal role in cytoskeletal 
organization and degradation of intermediate filaments (IFs). Loss of gigaxonin leads to 
dysregulation and accumulation of IFs such as NFs (NF-H, NF-M, NF-L), peripherin, alpha-
internexin, desmin, keratin and vimentin [2, 3]. Three mouse models have been developed 
for GAN by knocking out part of the endogenous GAN gene [4, 5, 6]. All three models 
mirror the IF dysregulation and peripheral nerve pathology seen in human GAN but exhibit 
a much milder phenotype.
During the course of a comprehensive pathologic characterization of the GAN KO mouse, 
we encountered the very early involvement of the autonomic nervous system (ANS). Here, 
described for the first time, we document the pronounced and widespread involvement of the 
enteric, parasympathetic and sympathetic ANS in the GAN KO mouse. Implications of this 
autonomic neuropathy for human GAN are discussed.
MATERIALS AND METHODS
Animals
GAN KO breeders with a deletion of GAN exons 3-5 (GAN/Y) were obtained from Y. Yang, 
and GAN KO breeders with a deletion of GAN exon 1 (GAN/J) were obtained from J.P. 
Julien; both lines were maintained at the University of North Carolina at Chapel Hill (UNC–
CH). GAN KO mice were generated by breeding a homozygous KO male with a 
Armao et al. Page 2





















heterozygous female. Consistent with the previous reports [4,6], heterozygous GAN mice 
are phenotypically normal and were used as controls. Mixed sex and age-matched 
littermates from both GAN KO models were used in these studies. Mice in the 4- and 12-
month-old cohorts for pathological studies were used as controls in other studies in the lab 
and had received vehicle injections 2-4 weeks prior to harvest. All procedures were 
performed in accordance with the Guide for the Care and Use of Laboratory Animals 
[DHHS Publication No. (NIH) 85-23] and approved by the UNC–CH Institutional Animal 
Care and Use Committee. All mice were kept on a 12 h light-dark cycle with access to food 
and water ad libitum.
One-hour stool collection
To assess gastrointestinal function, fecal pellet output and water content were assessed as 
previously described [7] in male GAN KO and heterozygote littermates at 3.5 (GAN/Y), 12 
(GAN/Y) and 22 (GAN/J) months of age. Each mouse was individually placed in a novel 
clean cage for a 60-min collection period. Immediately after expulsion, fecal pellets were 
collected and placed into pre-weighed 1.5 mL microcentrifuge tubes that were sealed to 
avoid evaporation. Tubes were weighed to obtain the wet weight of the stool and the stool 
was then dried overnight at 65°C and reweighed to obtain the dry weight. The fecal water 
content was calculated by taking the difference of the wet and dry weight expressed over the 
wet stool weight. All mice were tested at the same time each day (2-4 P.M.).
Tissue preparation
Mice were anesthetized at 4, 12 or 24 months of age with an overdose of avertin (0.04 mL/g 
of a 1.25% solution). For the 4-month-old cohort, tissues were immediately removed and 
drop-fixed in 10% neutralized buffered formalin (NBF). For the 12- and 24-month-old 
cohorts, mice were first perfused with phosphate-buffered saline containing 1 µg/mL heparin 
and then perfused with either 4% paraformaldehyde or 10 % NBF. Tissues were then 
removed and immediately fixed in 10% NBF at room-temperature for at least one week. 
Following fixation, whole spines were de-calcified overnight in Formical-4 and divided into 
cervical, thoracic and lumbar regions. Tissues were paraffin embedded and sectioned at 5 
μm thickness for histological analysis.
Histological analyses
Hematoxylin and eosin (H&E) staining was performed on tissue sections, and light 
microscopic evaluation for pathological abnormalities was performed with the examiner 
blind to genotype. Standard immunohistochemical procedures were used to immunostain 
serial sections of tissues with antibodies for IF proteins and to counterstain with 
hematoxylin. Analyses of IF aggregates in paravertebral sympathetic-chain ganglia were 
performed using rabbit anti-peripherin (Abcam: ab4666; 1:2500), rabbit anti-vimentin 
(Abcam, Ab92547; 1:250), rabbit anti-alpha-internexin (Abcam, Ab40758; 1:250) and 
mouse anti-NF-heavy chain, hypophosphorylated (Covance, SMI-32R; 1:5000). Rabbit anti-
peripherin (Abcam: Ab4666; 1:1000) was used to stain IF aggregates in the enteric nervous 
system. Images were captured at 60x and 100x with oil immersion using the Olympus BX61 
microscope (Olympus America), the QImaging Retiga 4000R camera (Surrey) and Volocity 
6.2.1 software (Perkin Elmer, Inc.). Figures were created using Adobe Photoshop CS4.
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Data are presented as the mean ± standard error of the mean. Data from the 1 h stool 
collection study were analyzed by two-way ANOVA with genotype and age as independent 
variables followed by post hoc analysis with Bonferroni's multiple comparison test using 




In 4-month-old GAN KO mice, light microscopic examination of H&E-stained sections 
revealed eosinophilic inclusions within neuronal cell bodies in the myenteric (Auerbach's) 
plexi of the esophagus, stomach and the small and large intestines and the submucosal 
(Meissner's) plexi of the s mall and large intestines (Fig. 1a). Histologically identical 
neuronal perikaryal inclusions were found in the myenteric and submucosal plexi of 12- and 
24-month-old GAN KO mice (Fig. 1b). The neuronal inclusions in the enteric ANS showed 
strong positivity for peripherin (Fig. 1c). Similar pathological features were present in both 
GAN/J and GAN/Y mice. Age-matched control mice had no neuronal inclusions in enteric 
ganglia.
Parasympathetic nervous system
In 4-month-old GAN KO mice, light microscopic examination of H&E-stained sections of 
systemic organs revealed numerous neuronal perikaryal inclusions within parasympathetic 
ganglia of the salivary glands (Fig. 1d), larynx, trachea, heart, bladder, kidney and 
gastrointestinal tract. In 24-month-old GAN KO mice, light microscopic examination of 
H&E-stained sections of systemic organs showed abundant neuronal perikaryal inclusions 
within parasympathetic ganglia of salivary glands, trachea, heart, bladder and 
gastrointestinal tract. The neuronal inclusions in the 4- and 24-month-old KO mice were 
histologically indistinguishable. Similar pathological features were present in both GAN/J 
and GAN/Y mice. Control mice had no neuronal inclusions in the parasympathetic nervous 
system.
Sympathetic nervous system
In 24-month-old GAN KO mice, light microscopic examination of H&E-stained sections of 
cervical, thoracic and lumbar paravertebral sympathetic ganglia and prevertebral 
sympathetic ganglia (celiac, superior/inferior mesenteric ganglia) revealed abundant, round 
to oval, brightly eosinophilic neuronal perikaryal inclusions (Fig 2a). Similar pathological 
features were present in GAN/J and GAN/Y mice. Control mice had no neuronal inclusions 
in sympathetic ganglia. Immunohistochemistry (IHC) for IF proteins showed diffuse, strong 
peripherin positivity within the neuronal inclusions and focal positivity within neuronal 
processes (Fig 2b). Controls showed only focal positivity within neuronal processes. IHC for 
vimentin and alpha internexin revealed immunoreactivity within the neuronal perikaryal 
inclusions and diffuse background staining of neuronal perikaryal cytoplasm and processes. 
Controls showed diffuse background staining of neuronal perikaryal cytoplasm and 
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processes. IHC for SMI-32 showed variable immunoreactivity of neuronal perikaryal 
cytoplasmic inclusions, ranging from negative to strongly positive, and focal 
immunoreactivity within neuronal perikaryal cytoplasm. Controls showed only focal 
immunoreactivity within neuronal perikaryal cytoplasm.
Central nervous system
In the 4-month-old GAN KO mice, light microscopic examination of H&E stained sections 
showed only occasional neuronal perikaryal inclusions in the cerebral cortex 
(Supplementary material Fig 1). There were no neuronal inclusions or axonal swellings in 
the spinal trigeminal nucleus of the medulla. Sections of cervical, thoracic and lumbosacral 
spinal cord showed no neuronal inclusions or axonal swellings. Preganglionic autonomic 
neurons within the intermediolateral (IML) columns of thoracic cord had no perikaryal 
inclusions. Age-matched control mice had no neuronal inclusions in the CNS.
In the 24-month-old GAN KO mice, light microscopic examination of H&E-stained sections 
revealed numerous neuronal perikaryal inclusions throughout the cerebral cortex. There 
were scattered neuronal inclusions and numerous axonal swellings in the spinal trigeminal 
nucleus of the medulla. Sections of cervical, thoracic and lumbosacral spinal cord showed 
numerous axonal swellings within the dorsal horns and the dorsal columns. Preganglionic 
autonomic neurons within the IML columns of thoracic cord had no perikaryal inclusion 
(Fig. 2c). Age-matched control mice had neither inclusions nor axonal swellings.
Gastrointestinal and urinary systems
Macroscopic examination of freshly dissected GAN KO and control mice at 24 months of 
age showed that GAN KO mice commonly had smaller intestinal tracts, including caecum, 
containing smaller fecal pellets in the large intestines when compared to intestinal tracts and 
fecal pellets in control mice (Supplementary Material Fig. 2a). At necropsy, the urinary 
bladders of GAN KO mice were frequently “full” when compared to control mice whose 
bladders were frequently “empty” (Supplementary Material Fig. 2b). After bladders were 
removed and manually emptied, GAN KO bladders were still noticeably enlarged compared 
to control mice (Supplementary Material Fig. 2c). Similar gross pathological features were 
present in both GAN/J and GAN/Y mice.
Based on macroscopic and microscopic abnormalities, gastrointestinal function was 
examined in 3.5-, 12-, and 22-month-old male GAN KO mice and controls by measuring 
stool expulsion, weight and water content over a 1 h period. Analysis of the total fecal 
pellets expelled showed that age significantly increased propulsive motility [F (2, 41) = 3.44, 
p < 0.05]. Additionally, GAN KO mice had increased fecal pellet expulsion compared to 
controls [F (1, 41) = 11.77, p < 0.01] with no difference in 3.5-month-old mice whereas 
significant differences were found in 12- (p < 0.05) and 22-month-old mice (p < 0.05) (Fig. 
3a). While the total dry weight of all fecal pellets over the 1 h period was similar between 
controls and GAN KO mice at all ages (data not shown), the average dry weight of the 
individual expelled fecal pellets were significantly less in GAN KO mice as compared to 
controls [F (1, 41) = 7.13, p < 0.05] and with increasing age [F (2, 41) = 13.78, p < 0.0001] 
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(Fig. 3b). The stool water content was unchanged between GAN KO and control littermates 
and for all age groups examined (Fig. 3c).
DISCUSSION
Although the behavioral phenotype of the GAN KO mouse model is mild and stands in 
contrast to the pronounced clinical findings in human GAN, the pathological phenotype of 
the GAN KO mouse model is strong and shares similar morphological features with the 
human disease. Most notably, the signature ultrastructural feature of human GAN, giant 
axonal swellings packed with accumulations of IFs [1], is very prominent in the GAN KO 
mouse. The GAN KO mouse also shows the involvement of both peripheral nerves and the 
CNS. Here, described for the first time in the GAN KO mouse, we document the presence of 
neuronal perikaryal inclusions in neurons of the enteric ANS and in postganglionic neurons 
of the sympathetic and parasympathetic ANS. These neuronal inclusions were much more 
frequent in neurons of the ANS than in neurons of the CNS in the 4-month-old KO mice and 
served as an easily identifiable early marker of GAN in the young KO mice. GAN/Y KO 
mice were initially reported to have a severe phenotype with the onset of motor function 
deficits as early as 6 months of age [4], but others have been unable to detect a motor 
phenotype in GAN KO mice up to 14-months-of-age [5, 6]. Here we show for the first time 
that abnormalities in gastrointestinal function can be detected in two different lines of GAN 
KO mice and at an earlier age than the onset of a motor phenotype. These findings suggest 
that the involvement of the ANS comes early in the overall disease progression of GAN.
ANS involvement in human GAN has been left largely uninvestigated. There is one 
published case report of a young child with GAN in whom ultrastructural examination of a 
rectal biopsy revealed abnormal neurons with perikaryal IFs “arranged into interwoven 
bundles” in the myenteric plexus [8]. Gastrointestinal symptoms, including lactose 
intolerance, constipation, obstipation, and reflux and regurgitation, are prominent and 
present in early childhood in GAN patients [1]. Additional signs and symptoms pointing to 
disturbances in autonomic regulation, such as reduction or loss of sweating ability, blood 
pressure instability with orthostatic hypotension, and heat intolerance are reported by GAN 
patient advocacy groups and professional organizations (http://www.hannahshopefund.org). 
These signs and symptoms of autonomic dysfunction appear early, supporting our findings 
in the GAN KO mice that ANS involvement is an early feature of GAN.
Preliminary assessment of gastrointestinal function in GAN KO mice showed increased 
stool expulsion as compared to age-matched controls. ANS dysfunction reflected in 
increased stool frequency compared to control mice has been reported in several mouse 
models of Parkinson's disease [9-11]. GAN KO mice had smaller fecal pellets as compared 
to controls, whereas the fecal water content was unchanged, suggesting that food intake 
and/or motility may be affected in GAN KO mice while water absorption in the gut is 
normal. Further tests examining food consumption, gastric emptying and gut motility are 
warranted to characterize the full spectrum of enteric dysfunction in GAN KO mice.
The identification of early, widespread ANS involvement in GAN KO mice should be 
considered as treatment strategies are developed for human GAN. Studies in GAN KO mice 
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have demonstrated that gigaxonin gene transfer can reverse the intracellular IF aggregates 
present in GAN [12], leading to gene transfer being the first proposed therapy for GAN. 
Validation of therapeutic efficacy and viral vector delivery systems with GAN KO models 
[4, 6] has provided the springboard for the development of the intrathecal (IT) scAAV9/JeT-
GAN viral vector employed in the Phase I gene therapy clinical trial for the treatment of 
children with GAN, recently announced by NIH/NINDS (https://clinicaltrials.gov/ct2/show/
NCT02362438). This gene transfer approach was not specifically designed to address the IF 
accumulations in the ANS. If this ANS pathology is present and clinically significant in 
humans, a future comprehensive treatment for GAN that includes the ANS may require an 
altered gene transfer approach or a combinatorial treatment strategy.
In conclusion, our systematic survey of neuropathologic alterations in the GAN KO mouse 
revealed neuronal intracytoplasmic abnormalities that were pronounced and pervasive 
throughout the ANS. An autonomic phenotype in GAN KO mice was demonstrated by 
abnormalities of gastrointestinal function. Such observations extend the pathologic 
characterization of the GAN KO mouse model and may provide an explanation for 
symptoms suggestive of ANS dysfunction in GAN patients. Further investigation of ANS 
dysfunction in human GAN may be warranted to (1) augment standardized, clinically 
meaningful measurements for the rate of unmitigated disease progression in natural history 
studies [13], (2) promote continued development of alternative outcome measures for 
therapeutic effect in clinical trials, and (3) expand quality of life (QoL) metrics for GAN 
patients and their families [14].
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Neuronal inclusions in the enteric and parasympathetic ANS of GAN KO mice. a GAN KO 
(4-month-old) enteric ganglia myenteric plexus of large intestine reveals eosinophilic 
neuronal perikaryal inclusions (arrows) (H&E; original magnification x100). b GAN KO 
(24-month-old) enteric ganglia myenteric plexus of large intestine shows eosinophilic 
inclusions within neuronal cell bodies (arrows) (H&E; original magnification x100). c GAN 
KO (12-month-old) enteric ganglia neuronal intracytoplasmic inclusions within the 
submucosal plexus (arrowheads) and myenteric plexus (arrows) of the small intestine 
(duodenum) show strong peripherin IF protein immunoreactivity (arrows) (peripherin IHC; 
original magnification x100). d GAN KO (4-month-old) parasympathetic ganglia in salivary 
gland reveals abundant eosinophilic neuronal perikaryal inclusions (arrows) (H&E; original 
magnification x60)
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Sympathetic neurons in the 24-month-old GAN KO mice. a. GAN KO postganglionic 
neurons within thoracic sympathetic paravertebral ganglia show abundant, eosinophilic 
neuronal perikaryal inclusions (arrows) (H&E; original magnification x40). b. GAN KO 
neuronal cytoplasmic inclusions within postganglionic neurons of thoracic sympathetic 
paravertebral ganglia show strong peripherin IF protein immunoreactivity (arrows) 
(Peripherin IHC; original magnification x40). c. GAN KO preganglionic sympathetic 
neurons within the intermediolateral (IML) columns of thoracic spinal cord show no 
inclusions (H&E; original magnification x100)
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Gastrointestinal function in GAN KO mice. Animals were placed individually in new cages 
and fecal pellets were collected over a 1-hour period. a. GAN KO mice have increased stool 
frequency compared with age-matched control mice at 12 and 22 months of age. b. Overall, 
GAN KO mice have a decreased average fecal pellet weight compared to control mice. c. 
The amount of fecal water is unchanged between GAN KO and control mice. Data were 
analyzed via two-way ANOVA (genotype × age) with Bonferroni's post-hoc analysis. #p < 
0.05, ##p < 0.01 (main effect of genotype indicated) and *p < 0.05 (post-hoc analysis). 
Results represent the average measurements for two trials ± SEM for 7-9 animals per cohort
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